+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report by Type (Squamous Cell Carcinoma, Large Cell Carcinoma), Treatment (Chemotherapy, Immunotherapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report by Type (Squamous Cell Carcinoma, Large Cell Carcinoma), Treatment (Chemotherapy, Immunotherapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report by Type (Squamous Cell Carcinoma, Large Cell Carcinoma), Treatment (Chemotherapy, Immunotherapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 5998905
Description Jump to:
The Non-small Cell Lung Cancer Therapeutics Market was valued at USD 21.46 billion in 2024, and is projected to reach USD 43.89 billion by 2030, rising at a CAGR of 12.71%. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

Non-small Cell Lung Cancer Therapeutics Market Report Highlights

  • The adenocarcinoma segment dominated the market in 2024 with a share of 43.39% in 2024 due to an increase in the population consuming tobacco and other products for smoking. The squamous cell carcinoma (SCC) segment is anticipated to witness the fastest CAGR over the forecast period.
  • The targeted therapy segment dominated the market in 2024 with a share of 50.66% in 2024. The immunotherapy segment is expected to grow at a significant CAGR over the forecast period.
  • The hospital pharmacy segment dominated the market with a share of 66.89% in 2024. The drug store and retail pharmacy segment is anticipated to witness a significant CAGR over the forecast period, owing to the increased availability of regulatory-approved drugs for consumption by patients seeking to cure NSCLC.
  • North America Non-small Cell Lung Cancer (NSCLC) therapeutics industry dominated globally with a market share of 35.41% in 2024. The Non-small Cell Lung Cancer (NSCLC) therapeutics industry in Asia-Pacific is witnessing rapid growth fueled by rising lung cancer incidence, government investment in oncology care, and growing regional partnerships to expand access to biologics and targeted drugs.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Non-small cell lung cancer therapeutics market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Non-small Cell Lung Cancer Therapeutics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.6. Pricing Analysis
Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis, USD Million, 2024 & 2030
4.3. Squamous Cell Carcinoma
4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Large Cell Carcinoma
4.5. Large Cell Carcinoma Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Adenocarcinoma
4.6.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis, USD Million, 2024 & 2030
5.3. Chemotherapy
5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.4. Targeted Therapy
5.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.5. Immunotherapy
5.5.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Movement Analysis, USD Million, 2024 & 2030
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Drug Store and Retail Pharmacy
6.4.1. Drug Store and Retail Pharmacy Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Online Pharmacy
6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2024 & 2030, USD Million
7.2. North America
7.2.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3. Europe
7.3.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.4. France
7.3.4.1. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.3. China
7.4.3.1. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.4. India
7.4.4.1. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Mylan N.V.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Teva Pharmaceutical Industries Ltd.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Sanofi
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Pfizer Inc.
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. GSK plc
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Novartis AG
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Bayer AG
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Eli Lilly and Company
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Merck & Co., Inc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of abbreviations
Table 3. North America Non-small Cell Lung Cancer Therapeutics Market, by region, 2018-2030 (USD Million)
Table 4. North America Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 5. North America Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 6. North America Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 7. US Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 8. US Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 9. US Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 10. Canada Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 11. Canada Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 12. Canada Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 13. Mexico Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 14. Mexico Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 15. Mexico Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 16. Europe Non-small Cell Lung Cancer Therapeutics Market, by region, 2018-2030 (USD Million)
Table 17. Europe Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 18. Europe Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 19. Europe Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 20. Germany Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 21. Germany Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 22. Germany Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 23. UK Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 24. UK Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 25. UK Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 26. France Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 27. France Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 28. France Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 29. Italy Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 30. Italy Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 31. Italy Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 32. Spain Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 33. Spain Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 34. Spain Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 35. Denmark Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 36. Denmark Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 37. Denmark Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 38. Sweden Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 39. Sweden Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 40. Sweden Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 41. Norway Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 42. Norway Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 43. Norway Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 44. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market, by region, 2018-2030 (USD Million)
Table 45. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 46. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 47. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 48. China Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 49. China Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 50. China Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 51. Japan Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 52. Japan Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 53. Japan Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 54. India Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 55. India Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 56. India Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 57. South Korea Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 58. South Korea Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 59. South Korea Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 60. Australia Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 61. Australia Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 62. Australia Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 63. Thailand Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 64. Thailand Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 65. Thailand Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 66. Latin America Non-small Cell Lung Cancer Therapeutics Market, by region, 2018-2030 (USD Million)
Table 67. Latin America Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 68. Latin America Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 69. Latin America Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 70. Brazil Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 71. Brazil Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 72. Brazil Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 73. Argentina Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 74. Argentina Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 75. Argentina Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 76. MEA Non-small Cell Lung Cancer Therapeutics Market, by region, 2018-2030 (USD Million)
Table 77. MEA Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 78. MEA Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 79. MEA Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 80. South Africa Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 81. South Africa Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 82. South Africa Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 83. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 84. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 85. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 86. UAE Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 87. UAE Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 88. UAE Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
Table 89. Kuwait Non-small Cell Lung Cancer Therapeutics Market, by type, 2018-2030 (USD Million)
Table 90. Kuwait Non-small Cell Lung Cancer Therapeutics Market, by treatment, 2018-2030 (USD Million)
Table 91. Kuwait Non-small Cell Lung Cancer Therapeutics Market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Market research process
Figure 3 Information Procurement
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value Chain-Based Sizing & Forecasting
Figure 7 Market Formulation & Validation
Figure 8 Non-small Cell Lung Cancer Therapeutics, Market Segmentation
Figure 9 Market Snapshot, 2024
Figure 10 Market Trends & Outlook
Figure 11 Market Driver Relevance Analysis (Current & Future Impact)
Figure 12 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 14 Porter’s Five Forces Analysis
Figure 15 Global Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis
Figure 16 Global Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis
Figure 17 Global Non-small Cell Lung Cancer Therapeutics Market, for Distribution Channel, 2018-2030 (USD Million)
Figure 18 Regional Marketplace: Key Takeaways
Figure 19 Regional Outlook, 2024 & 2030
Figure 20 Global Non-small Cell Lung Cancer Therapeutics Market: Region Movement Analysis
Figure 21 North America Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 22 U.S. Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 23 Canada Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 24 Mexico Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 25 Europe Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 26 Germany Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 27 UK Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 28 France Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 29 Italy Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 30 Spain Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 31 Denmark Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 32 Sweden Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 33 Norway Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 34 Asia Pacific Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 35 Japan Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 36 China Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 37 India Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 38 Australia Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 39 Thailand Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 40 South Korea Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 41 Latin America Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 42 Brazil Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 43 Argentina Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 44 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 45 South Africa Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 46 Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 47 UAE Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)
Figure 48 Kuwait Non-small Cell Lung Cancer Therapeutics Market, 2018-2030 (USD Million)

Companies Mentioned

The major companies featured in this Non-small Cell Lung Cancer Therapeutics market report include:
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages100
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 21.46 Billion
Forecasted Market Value ( USD ) by 2030 $ 43.89 Billion
Compound Annual Growth Rate12.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, Distribution Channel - Global Forecast to 2030 - Product Image

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, Distribution Channel - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Market Report 2025 - Product Image

Non-Small Cell Lung Cancer (NSCLC) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Squamous Non-Small Cell Lung Cancer Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Squamous Non-Small Cell Lung Cancer Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 99 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.